Cargando…

P04-47. High-titer autologous and heterologous neutralizing antibody activity in acute SIV-infection

Detalles Bibliográficos
Autores principales:	Schweighardt, B, Ma, Z, Petropoulos, CJ, Miller, CJ, Wrin, T
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2009
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2767979/ http://dx.doi.org/10.1186/1742-4690-6-S3-P75

Ejemplares similares

P04-50 LB. Prevalence of cross-reactive HIV-1 neutralizing activity in HIV-1 infected patients with rapid or slow disease progression
por: van Gils, MJ, et al.
Publicado: (2009)

P05-14 LB. Analysis of virus swarms to identify vaccine immunogens with improved exposure of epitopes recognized by broadly neutralizing antibodies
por: Berman, P, et al.
Publicado: (2009)

P04-41. Kinetics of antibody neutralization and viral evolution following envelope vaccination in SIV-infected rhesus monkeys
por: Basavapathruni, A, et al.
Publicado: (2009)

Intrasubtype C superinfected individuals mount delayed and low-titer autologous neutralizing antibody responses prior to superinfection
por: Basu, D, et al.
Publicado: (2012)

Novel vomputational methods for predicting epitopes of potent and broadly neutralizing HIV-1 antibodies
por: Evans, MC, et al.
Publicado: (2012)

P04-55 LB. Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes
por: Zolla-Pazner, S, et al.
Publicado: (2009)

P03-07. Autologous neutralizing antibodies that select viral escape variants emerge late after SIV infection of rhesus monkeys
por: Yeh, WW, et al.
Publicado: (2009)

P04-03. Cross-clade neutralization analysis of plasmas from clade B, C and CRF01_AE HIV-infected donors
por: Binley, J, et al.
Publicado: (2009)

P04-04. The specific phospholipid binding and neutralizing activities of the anti-HIV antibody 4E10 are separable
por: Xu, H, et al.
Publicado: (2009)

Predicting HIV-1 broadly neutralizing antibody epitope networks using neutralization titers and a novel computational method
por: Evans, Mark C, et al.
Publicado: (2014)

Postnatally-transmitted HIV-1 variants are efficient at dendritic cell trans-infection and sensitive to autologous and heterologous neutralization
por: Fouda, GG, et al.
Publicado: (2012)

P04-29. HIV-1 neutralizing antibodies inhibit plasmacytoid dendritic cells infection
por: Lederle, A, et al.
Publicado: (2009)

P04-09. Induction of cross-clade neutralizing antibodies with a prime/boost vaccine strategy focused on a neutralizing epitope
por: Zolla-Pazner, S, et al.
Publicado: (2009)

P04-15. Prevalence of broadly neutralizing antibody responses during acute/early HIV infection
por: Mikell, I, et al.
Publicado: (2009)

P04-26. Immunological tolerance prevents the expression of a broadly reactive neutralizing HIV-1 antibody
por: Verkoczy, L, et al.
Publicado: (2009)

P04-37. Kinetic and thermodynamic factors determine HIV-1 neutralizing potency of MPER-specific antibodies
por: Ruprecht, C, et al.
Publicado: (2009)

P04-40. Dissecting pre- and post-attachment activity of HIV-1 entry inhibitors and neutralizing antibodies
por: Berlinger, L, et al.
Publicado: (2009)

P04-43. Neutralizing antibody responses against conformational envelope epitopes in early HIV-1 infection
por: Bar, KJ, et al.
Publicado: (2009)

Mapping epitopes on CRF01_AE viruses recognized by broadly neutralizing antibodies in sera from elite neutralizers from North America and Thailand
por: O'Rourke, SM, et al.
Publicado: (2012)

P04-10. Neutralization of Tier 1 and Tier 2 pseudoviruses by human anti-V3 monoclonal antibodies
por: Gorny, MK, et al.
Publicado: (2009)

P04-02. Increased breadth and potency of the neutralizing antibody response among dually-HIV-1-infected individuals
por: Powell, RL, et al.
Publicado: (2009)

P04-18. Comparison of HIV neutralization assays for use in vaccine research and clinical trials, phase II: results from the NeutNet working group
por: Scarlatti, G, et al.
Publicado: (2009)

Mutations in the V1 domain of Thai CRF01-AE viruses that confer sensitivity/resistance to broadly neutralizing antibodies
por: O'Rourke, S, et al.
Publicado: (2012)

P04.47. Parents’ satisfaction in a department of integrative pediatric oncology: a ten year experience
por: Laengler, A, et al.
Publicado: (2012)

P04-38. Crystal structure of gp120 in complex with the CD4-binding-site antibody b13 suggests precise targeting is needed for neutralization
por: Zhou, T, et al.
Publicado: (2009)

P04-06. Evolution of an anti-MPER gp41 antibody response that mediates broad HIV-1 cross-neutralization
por: Gray, E, et al.
Publicado: (2009)

P04-51 LB. The epitopes of two newly identified broad and potent neutralizing antibodies, PG9 and PG16
por: Walker, L, et al.
Publicado: (2009)

P18-04. MVA-nef vaccination induces specific T-cell responses exerting functions associated with non-progressive disease in HIV-1 infected individuals
por: Kutscher, S, et al.
Publicado: (2009)

Protection against highly pathogenic SIV by BCG-SIV recombinant priming and attenuated replicating vaccinia-SIV recombinant boosting
por: Zhang, X, et al.
Publicado: (2012)

P04-24. Frequencies of HIV Env-specific B cells and neutralizing antibodies during DNA-prime/protein-boost immunization with three different Env immunogens*
por: Tawde, P, et al.
Publicado: (2009)

P04-53 LB. Potent and broad HIV-specific neutralizing antibodies in infants are not associated with prevention of mother to infant HIV transmission
por: Lynch, J, et al.
Publicado: (2009)

CD40L adjuvant for DNA/MVA vaccine: enhanced protection from acquisition of neutralization sensitive & neutralization resistant mucosal SIV infections
por: Kwa, S, et al.
Publicado: (2012)

Superinfection by discordant subtypes of HIV-1 does not enhance the neutralizing antibody response against autologous virus
por: Mayr, LM, et al.
Publicado: (2012)

P04-52 LB. The importance of well-defined HIV-1 neutralization assays
por: Balla-Jhagjhoorsingh, SS, et al.
Publicado: (2009)

P19-57 LB. Gene-based vaccination protects against mucosal infection by a heterologous highly pathogenic SIV isolate in rhesus monkeys
por: Letvin, N, et al.
Publicado: (2009)

P15-04. Development and implementation of an international proficiency testing program for a neutralizing antibody assay for HIV-1 in TZM-bl cells
por: Todd, CA, et al.
Publicado: (2009)

P04-28. Breadth and magnitude of neutralizing antibody responses in subjects infected with HIV-1 subtype D or recombinants in Rakai district, Uganda
por: Eller, L, et al.
Publicado: (2009)

Elevated titers of anti-ribosomal-P antibodies in systemic lupus erythematosus
por: Zandman-Goddard, G, et al.
Publicado: (2005)

P05-04. Neutralizing antibodies induced by immunization with liposomal gp41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes
por: Matyas, GR, et al.
Publicado: (2009)

Replication kinetics and persistence of a conditionally live attenuated SIV (SIVrtTA) in vivo confers protection against homologous and heterologous wild-type challenge in macaques
por: Berry, Neil, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_koc1o9g384ctm6bkpn7k716gbq